Goldman Sachs Group Inc. Sells 600,099 Shares of Perspective Therapeutics, Inc. $CATX

Goldman Sachs Group Inc. trimmed its holdings in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 66.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 302,819 shares of the company’s stock after selling 600,099 shares during the quarter. Goldman Sachs Group Inc. owned 0.41% of Perspective Therapeutics worth $645,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC grew its holdings in Perspective Therapeutics by 71.1% during the 1st quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company’s stock worth $4,738,000 after acquiring an additional 924,196 shares during the last quarter. Millennium Management LLC bought a new stake in Perspective Therapeutics during the 4th quarter worth approximately $4,132,000. Nuveen LLC bought a new stake in Perspective Therapeutics during the 1st quarter worth approximately $2,647,000. Two Sigma Investments LP bought a new stake in Perspective Therapeutics during the 4th quarter worth approximately $2,075,000. Finally, Northern Trust Corp grew its holdings in Perspective Therapeutics by 2.8% during the 4th quarter. Northern Trust Corp now owns 487,273 shares of the company’s stock worth $1,554,000 after acquiring an additional 13,115 shares during the last quarter. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Stock Up 2.8%

CATX opened at $3.26 on Thursday. Perspective Therapeutics, Inc. has a 1-year low of $1.60 and a 1-year high of $13.56. The company has a fifty day moving average price of $3.64 and a two-hundred day moving average price of $3.04.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CATX. B. Riley reissued a “buy” rating and set a $12.00 target price (up from $9.00) on shares of Perspective Therapeutics in a report on Monday, June 23rd. Royal Bank Of Canada raised shares of Perspective Therapeutics from an “outperform” rating to a “moderate buy” rating and upped their price objective for the company from $15.00 to $16.00 in a research note on Tuesday, June 3rd. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Perspective Therapeutics in a research note on Friday, September 19th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Monday, September 15th. Finally, Lifesci Capital raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Saturday, July 12th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Perspective Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $12.56.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.